Compare Asana Inc. (ASAN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Merck & Co., Inc. — how do they compare? Asana Inc. trades at $8.97 (market cap $2.13B), while Merck & Co., Inc. trades at $133.56 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 151.1× Asana Inc.'s market cap, and Merck & Co., Inc. pays a 2.61% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.
| ASAN | MRK | |
|---|---|---|
Market Cap | $2.13B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $131.84 |
52-Week Low | $5.46 | $77.60 |
Enterprise Value | $1.96B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $8.96, down 2.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth continues, reaching $723.88M in 2025, while net losses persist at -$255.54M. Recent Q1 2026 earnings beat expectations, and the company secured FedRAMP authorization and acquired StackAI to enhance AI capabilities, signaling strategic growth initiatives.
The outlook hinges on Asana's path to profitability amid high competition; analyst consensus is mixed with a $10.33 price target. Key risks include sustained losses and competitive pressure from larger tech firms, but AI product adoption and government contracts offer potential upside if execution improves.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
